SLS-009
Undisclosed
DiscoveryResearch
Key Facts
About Seelos Therapeutics
Seelos Therapeutics is a publicly traded, clinical-stage biopharmaceutical company focused on the efficient development of therapies for CNS disorders and rare diseases. Founded in 2016, its strategy centers on acquiring and developing a diversified portfolio of assets, including small molecules, psychedelics, and gene therapies, often through repurposing or reformulating known compounds. The company's lead asset, SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB), is in a registration-directed Phase 2 study, representing its most advanced program. Seelos operates as a lean organization, aiming to de-risk development by targeting serious conditions with limited treatment options.
View full company profileOther Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |
| Therapeutic Programs | Agathos Biologics | Pre-clinical |